Quick Answer
Atea Pharmaceuticals, Inc. reported Diluted EPS of $1.94 per share (loss) for fiscal year 2025.
Atea Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.94 | +3.0% |
| 2024 | -$2.00 | -22.7% |
| 2023 | -$1.63 | -17.3% |
| 2022 | -$1.39 | -201.5% |
| 2021 | $1.37 | +368.6% |
| 2020 | -$0.51 | +63.3% |
| 2019 | -$1.39 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.53 | -43.2% | -20.5% |
| June 30, 2025 | -$0.44 | +8.3% | -10.0% |
| March 31, 2025 | -$0.40 | +46.7% | -8.1% |
| September 30, 2024 | -$0.37 | +7.5% | +22.9% |
| June 30, 2024 | -$0.48 | -41.2% | +36.0% |
| March 31, 2024 | -$0.75 | -74.4% | -87.5% |
| September 30, 2023 | -$0.40 | -300.0% | -17.6% |
| June 30, 2023 | -$0.34 | +10.5% | +20.9% |
- Atea Pharmaceuticals, Inc. showed an increase of +3.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Atea Pharmaceuticals, Inc.’s diluted eps has declined by 39.6% (from $1.39 per share (loss) to $1.94 per share (loss)).
- The most recent figure is from Atea Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: